Innovation

Modulation of GSK3ß Activity May Offer Disease Treatments

University of Vermont
posted on 07/29/2008

Abnormal levels of GSK3ß activity have been associated with a wide range of diseases, including neurological conditions, diabetes, and cancer.
Effective treatments for these diseases may be based on the newly-discovered ability of p38 mitogen-activated protein kinase (MAPK) to phosphorylate GSK3ß activity.

Suggested Uses

Treatment of diseases associated with elevated or reduced levels of GSK3ß activity, such as:

  • Neurological disorders including stroke and Alheimer’s disease.
  • Cancer.
  • Diabetes.

Advantages

  • Offers new approach to increasing or decreasing GSK3ß activity.
  • Potential applications in a wide variety of clinical disorders.
  • Based on well established relationship between abnormal GSK3ß levels and specific diseases.

Innovation Details
 

Detailed Description

A newly discovered approach to the mediation of a process that regulates cell function may lead to effective treatments for a variety of diseases.


GSK3ß, one of two genes known to encode a type of enzyme called Glycogen Synthase Kinase-3, regulates diverse cell functions such as signaling, gene expression, and metabolism through phosphorylation of cellular substrates.


GSK3ß and Disease
Abnormally high and low levels of GSK3ß activity have been associated with a wide variety of disorders, including neurological diseases, diabetes, and cancer.


Future treatments for these disorders may be based on the newly discovered ability of p38 mitogen-activated protein kinase (MAPK) to phosphorylate GSK3ß activity.


Modulating GSK3ß
In conditions associated with reduced GSK3ß activity, such as cancer and diabetes, treatments would be intended to reduce cell survival by inhibiting the phosphorylation of GSK3ß.


In conditions associated with elevated GSK3ß activity, particularly neurological conditions such as stroke, head trauma, and Alzheimer’s disease, treatments would be intended to increase cell survival by increasing the level of GSK3ß phosphorylation.


In potential disease therapies, a synthetic peptide of GSK3ß (or similar small molecule) could be used as a specific GSK3ß blocker. Also, antibodies that recognize the peptide may prove useful in diagnosing reduced or elevated GSK3ß activity levels.

File Number: 335 

Other Information:

*Next Steps*
Further research will be conducted on the modulation of GSK3ß activity. Commercial laboratories may conduct additional studies to investigate potential clinical applications.


IP Protection


License Online

This innovation currently is not available for online licensing. Please contact the case manager at University of Vermont for more information.

Request more info via email request more info
People

Principal Investigator:

Mercedes Rincon Mercedes Rincon

Innovations (1)

Publications (6)



Download Technology Brief (PDF)


Followed By

Follow this innovation



No one is following this innovation.

Organization
Profile
Related Tags

Find more innovations


February 11, 2009

7,868 members 17,196 innovations 152 organizations

Browse

Dr. Jörg Knäblein – Technology Scouting, Bayer Schering Pharma AG

"Through the iBridge Network, I was able to find a mouse model I was looking for. The collaboration available through the iBridge Network is crucial in driving innovation and I'll continue using it as a valued resource."  read more...